A new device and methods that allow for improved sequestration and preservation of harvested analytes and biomolecules from biofluid samples is defined. The new device and methods relate to an improved dried biofluid collection substrate that is absorbent and contains a plurality of affinity ligands located within defined sample collection regions for enhanced analyte collection and storage. The device and methods allow for simple, safe and reliable ambient temperature collection and preservation of molecules captured from biological and environmental fluids in quantities suitable for analysis and diagnostic testing.

Embodiments described herein provide materials and methods for the absorption or filtration of various species and analytes. In some cases, the materials may be used to remove or reduce the amount of a substance in vapor sample (e.g., cigarette smoke).

The present invention relates to activated carbon sorbents including nitrogen. In various embodiments, the present invention provides an activated carbon sorbent including a halogen- or halide-promoted activated carbon, the activated carbon sorbent particles including nitrogen in a surface layer of the sorbent particles. In various embodiments, the present invention provides a method of reducing the pollutant content in a pollutant-containing gas using the activated carbon sorbent. In various embodiments, the activated carbon sorbent can remove mercury from a mercury-containing gas that includes sulfur(VI) such as SO.sub.3 more efficiently than other sorbents.

Sorbent compositions that includes a base sorbent material having a high porosity and surface area and a boron-selective agent are particularly useful for the sequestration of boron from waste materials such as coal combustion residual leachate (CCRs). By using a boron-selective agent in conjunction with a high surface area base sorbent material such as activated carbon or biochar, a sorbent composition with a high capacity for sequestering boron at relatively low cost is provided.

This invention relates to a hybrid ligand, a hybrid biomimetic chromedia and a preparing method and a use thereof, wherein the hybrid biomimetic chromedia takes hydrophilic porous microsphere as a substrate in chromatography, activated with allyl bromide and undergoing bromo-alcoholization with N-bromosuccinimide, then coupled with the hybrid ligands. The sequence of the hybrid ligand is phenylalanine-tyrosine-glutamine-5-aminobenzimidazole. The hybrid biomimetic chromedia has both of the two functional groups of phenylalanine-tyrosine-glutamine tripeptide and aminobenzimidazole, while maintaining the high antibody selectivity of polypeptide ligand, hydrophobic electric charge inductive ligand is introduced to achieve more moderate elution requirement, realizing effective antibody separation.

Methods for isolating proteins from a honey sample are provided. The methods include contacting the honey sample with a substrate functionalized with one or more reactive dyes and recovering proteins associated with the substrate. Methods for detecting proteins in a honey sample and assessing the risk of colony collapse disorder are also provided.

Sorbent compositions that include a base sorbent material having a high porosity and surface area and a boron-selective agent are particularly useful for the sequestration of boron from waste materials such as coal combustion residual leachate (CCRs). By using a boron-selective agent in conjunction with a high surface area base sorbent material such as activated carbon or biochar, a sorbent composition with a high capacity for sequestering boron at relatively low cost is provided.

This present invention discloses a bifunctional adsorptive material capable of adsorbing both cations and anions in aqueous phase, obtainable by synthesizing aluminum ion doped SBA-15 molecular sieves from P123 triblock copolymers, tetraethoxysilane, and aluminum isopropoxide to obtain multiple cationic active adsorption sites, and by grafting large sterically hindered organic groups onto the surface of Al-SBA-15 to obtain multiple anionic active adsorption sites. This kind of adsorptive material has two types of adsorption sites for ions of opposite charges. The large sterically hindered organic groups prevent spontaneous recombination reaction between the two types of adsorption sites, enabling the adsorptive material to have excellent adsorption capacity for wastewater treatment involving both cations and anions.

A composite sorbent composition comprising a polymeric adsorbent; and an extractant having the formula (I), or hydrate in thereof, wherein X is O or S, A1 and A2 are each independently —C(O)— or —C(R′)(R″)— wherein R′, and R″ are each independently hydrogen, halogen, hydroxyl, cyano, nitro, amino, —CHO, —COOH, C1-12 alkyl, C1-4 alkoxy, C1-4 alkylamino, C1-2 haloalkyl, C1-2 haloalkoxy, C1-12 cycloalkyl, C6-12 aryl, C7-13 arylalkyl, C3-12 heteroaryl, C1-12 heteroalkyl, or C4-12 heteroarylalkyl, Z is a covalent bond, —S—, —O—, —SO2—, —SO—, —P(R)(═O)—, —NR—, -C(O)-, -C(O)NH-, —C(═N—R)—, or —C(R′)(R″)— wherein R, R′, and R″ are each independently hydrogen, halogen, hydroxyl, cyano, nitro, amino, —CHO, —COOH, —C(O)NH2, C1-12 alkyl, C1-12 alkoxy, C1-12 alkylamino, C1-4 haloalkyl, C1-4 haloalkoxy, C4-12 cycloalkyl, C6-12 aryl, C7-13 arylalkyl, C3-12 heterocycloalkyl, C3-12 heteroaryl, C1-12 heteroalkyl, or C4-12 heteroarylalkyl, and R1 and R2 are each independently hydrogen, halogen, hydroxyl, cyano, nitro, amino, or a substituted or unsubstituted monovalent C1-40 hydrocarbon.

##STR00001##

The present disclosure relates to non-hemolytic adsorbent compositions useful for isolating, enumerating, accounting, and removing the disease-causing toxic constituents in the blood. The said compositions are useful in identifying the disease, disease status, and validating the efficacy of the therapeutic treatment being administered for the treatment of the disease. Methods for isolating, enumerating, accounting, and removing disease-causing toxic constituents in the blood as well as monitoring the disease status and validating the efficacy of the therapeutic treatment being administered for the treatment of the disease are disclosed.